A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Alemtuzumab is an efficacious therapy for active relapsing-remitting MS (RRMS), but its use is complicated by the potential development of secondary autoimmunity.(1) Recent data from phase 3 extension studies confirm thyroid autoimmunity as the most abundant entity of secondary autoimmunity found in up to 30%-40% of treated patients, with most events mild or moderate in severity. Data also show low rates of previously known autoimmune phenomena, such as immune thrombocytopenia and nephropathy.(2) However, further entities including sarcoidosis, vitiligo, and hemophagocytic lymphohistiocytosis (HLH) have been described in real-world cohorts.(3) Here, we present a case of another lymphoproliferative syndrome, namely idiopathic multicentric Castleman disease (iMCD), after alemtuzumab treatment.Keywords
This publication has 6 references indexed in Scilit:
- Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumabNeurology, 2018
- Alemtuzumab CARE-MS II 5-year follow-upNeurology, 2017
- Idiopathic multicentric Castleman's disease: a systematic literature reviewThe Lancet Haematology, 2016
- The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s diseaseBMC Pediatrics, 2014
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- A Novel Strategy To Reduce the Immunogenicity of Biological TherapiesThe Journal of Immunology, 2010